Andrew T Gewirtz
Overview
Explore the profile of Andrew T Gewirtz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
229
Citations
11969
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rytter H, Naimi S, Wu G, Lewis J, Duquesnoy M, Vigue L, et al.
Gut
. 2025 Jan;
PMID: 39870396
Background: Non-absorbed dietary emulsifiers, including carboxymethylcellulose (CMC), directly disturb intestinal microbiota, thereby promoting chronic intestinal inflammation in mice. A randomised controlled-feeding study (Functional Research on Emulsifiers in Humans, FRESH) found...
2.
Kordahi M, Daniel N, Gewirtz A, Chassaing B
Gut Microbes
. 2025 Jan;
17(1):2455790.
PMID: 39865067
Metabolic syndrome is, in humans, associated with alterations in the composition and localization of the intestinal microbiota, including encroachment of bacteria within the colon's inner mucus layer. Possible promoters of...
3.
Wang Y, Allan D, Gewirtz A
PLoS One
. 2025 Jan;
20(1):e0317248.
PMID: 39804860
Microbiota-induced production of IL-22 by type 3 innate lymphoid cells (ILC3) plays an important role in maintaining intestinal health. Such IL-22 production is driven, in part, by IL-23 produced by...
4.
Gewirtz A, Chassaing B
Brain Behav Immun
. 2024 Oct;
123:884-885.
PMID: 39481493
No abstract available.
5.
Lauer J, Kirby M, Muhihi A, Ulenga N, Aboud S, Liu E, et al.
J Nutr
. 2024 Sep;
154(11):3400-3406.
PMID: 39278411
Background: Environmental enteric dysfunction (EED) is an acquired, subclinical state of intestinal inflammation common in children and adults in low-income and middle-income countries. Although vitamin D-3 supplementation has purported anti-inflammatory...
6.
Lieber C, Kang H, Sobolik E, Sticher Z, Ngo V, Gewirtz A, et al.
J Virol
. 2024 Aug;
98(9):e0090524.
PMID: 39207133
Importance: Four years after the onset of the global coronavirus disease 2019 (COVID-19) pandemic, the immunocompromised are at greatest risk of developing life-threatening severe disease. However, specific treatment plans for...
7.
Tejada J, Walters W, Wang Y, Kordahi M, Chassaing B, Pickard J, et al.
Gut Microbes
. 2024 Aug;
16(1):2392872.
PMID: 39189608
We sought to better understand how intestinal microbiota confer protection against () infection (CDI). We utilized gnotobiotic altered Schaedler flora (ASF) mice, which lack the abnormalities of germfree (GF) mice...
8.
Suppakitjanusant P, Wang Y, Sivapiromrat A, Hu C, Binongo J, Hunt W, et al.
J Clin Transl Endocrinol
. 2024 Aug;
37:100362.
PMID: 39188269
Background: Cystic fibrosis (CF) is a multi-organ disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). Individuals with CF often have gastrointestinal (GI) dysbiosis due to chronic...
9.
Ngo V, Wang Y, Wang Y, Shi Z, Britton R, Zou J, et al.
Cell Mol Gastroenterol Hepatol
. 2024 Aug;
18(5):101393.
PMID: 39179176
Background & Aims: The protection provided by rotavirus (RV) vaccines is highly heterogeneous among individuals. We hypothesized that microbiota composition might influence RV vaccine efficacy. Methods: First, we examined the...
10.
Yeoh B, Gewirtz A, Vijay-Kumar M
Gastro Hep Adv
. 2024 Aug;
3(3):333-335.
PMID: 39131148
Studies in rodents suggest that inulin supplements may be carcinogenic. We present a case implicating that this risk extends to humans. A healthy male from a family lacking history of...